RI New York 2019: SDGs and impact investing

The panel will look at how the SDGs are creating change and value through the business and institutional investment chain, what the investment benchmarking of companies against SDG progress looks like, why do it, as well as how asset owners and society at large interpret successful SDG investment.

Bowen will discuss the latest and upcoming research at the Access to Medicine Foundation, and how investors have been using the Access to Medicine Index and Antimicrobial Resistance (AMR) Benchmark, in their impact investing strategies, as well as engagement and stewardship activities.

Speakers:

• Bowen Gu, Investor Engagement Manager, Access to Medicine Foundation

• Namtse Namgyal, Head of Institutional Sales, North America, Trucost, part of S&P Global 

• John Levy, Director of Impact, FT Real Asset Advisors, Franklin Templeton

There is increasing recognition that access to medicine is material for the pharmaceutical industry. More than 95 investors - together managing assets of more than USD 13 trillion - have signed the Access to Medicine Index Investor Statement and committed to using the Index in their investment analysis and engagements with companies. Find out more about our work with investors here.